Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 12/20 | 0.53 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.47 |
| ▸ | CACNB1 | Q02641 | 2/20 | 0.47 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634872 | 0.92 | CACNA2D1 (0.54) | KCNH2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5634382 | 0.92 | CACNA2D1 (0.54) | KCNH2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5634736 | 0.88 | CACNA2D1 (0.56) | KCNH2CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL5633709 | 0.86 | CYP3A4 (0.51) | CACNA2D1CACNA1BCACNB1CACNA1CBCHE | |
| SCHEMBL5634371 | 0.82 | CACNA2D1 (0.54) | CACNA2D1CACNA1BCACNB1CACNA1CBCHE | |
| SCHEMBL5634401 | 0.78 | CACNA2D1 (0.56) | CACNA2D1CACNA1BCACNB1CACNA1CBCHE | |
| SCHEMBL5633428 | 0.77 | CACNA2D1 (0.55) | CACNA2D1CACNA1BCACNB1CACNA1CBCHE | |
| SCHEMBL8298777 | 0.74 | CKS1B (0.51) | — | |
| SCHEMBL5634490 | 0.72 | CACNA2D1 (0.52) | CACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL27653824 | 0.72 | LMNA (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244758-B2 | N-type calcium channel blockers | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-07-17 | — | — | US | claimed |
| US-20050014748-A1 | N-type calcium channel blockers | NEUROMED TECHNOLOGIES INC. | 2005-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014748-A1 | N-type calcium channel blockers | CACNA1B, CACNA1C, CACNA1I | KCNH2 33/4885CACNA2D1 30/4885CACNA1B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.